IFP Advisors’s Akebia Therapeutics AKBA Stock Holding History

IFP Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$189	Buy	+166	New	+$198	﹤0.01%	4859
2026 Q1	–	Sell	-52	Closed	-$84	–	5020
2025 Q4	$84	Buy	52 +9	+21%	+$19	﹤0.01%	4626
2025 Q3	$117	Buy	+43	New	+$143	﹤0.01%	4517
2025 Q2	–	Hold	0	–	–	–	3345
2021 Q4	–	Sell	-152	Closed	-$1K	–	3376
2021 Q3	$1K	Buy	152 +50	+49%	+$143	﹤0.01%	2966
2021 Q2	$0	Buy	+102	New	+$343	﹤0.01%	3049
2020 Q4	–	Sell	-47	Closed	-$137	–	2927
2020 Q3	$0	Buy	+47	New	+$412	﹤0.01%	2833
2018 Q3	–	Sell	-28	Closed	–	–	3804
2018 Q2	$0	Sell	28 -400	-93%	-$4K	﹤0.01%	3856
2018 Q1	$6K	Hold	428	–	–	﹤0.01%	3044
2017 Q4	$6K	Buy	428 +400	+1,429%	+$6.63K	﹤0.01%	3090
2017 Q3	$1K	Hold	28	–	–	﹤0.01%	3865
2017 Q2	$0	Hold	28	–	–	﹤0.01%	4061
2017 Q1	$0	Hold	28	–	–	﹤0.01%	3966
2016 Q4	$0	Hold	28	–	–	﹤0.01%	3958
2016 Q3	$0	Buy	+28	New	+$238	﹤0.01%	3884
2016 Q1	–	Sell	-77	Closed	-$1K	–	2371
2015 Q4	$1K	Buy	+77	New	+$786	﹤0.01%	3470

Other funds holding AKBA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

IFP Advisors's AKBA Position: Q2 2026 in Review

IFP Advisors opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 166 shares worth $189. The stake represents ﹤0.01% of the portfolio and ranks #4859 among its holdings. This is a return to the name: IFP Advisors previously reported a position in AKBA as recently as Q4 2025.

IFP Advisors first reported a position in AKBA in Q4 2015 and has held it in 15 quarters since. The position peaked at $6K in Q1 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

IFP Advisors held 166 shares of Akebia Therapeutics worth $189 as of Q2 2026.
Akebia Therapeutics was a new IFP Advisors position in Q2 2026.
Akebia Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4859 holding.
IFP Advisors first reported a position in Akebia Therapeutics in Q4 2015 and has held it in 15 quarters since.
IFP Advisors's Akebia Therapeutics position peaked at $6K in Q1 2018.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.